The eSVS® Mesh Post-Marketing Trial

Not Applicable

Terminated

• Conditions: Myocardial Ischemia; Heart Diseases; Arterial Occlusive Diseases; Coronary Artery Disease; Coronary Disease; Arteriosclerosis; Cardiovascular Diseases; Vascular Diseases
• Interventions: Device: eSVS Mesh

• Registration Number: NCT01520311
• Lead Sponsor: Kips Bay Medical, Inc.

Brief Summary

The purpose of this study is to evaluate patency rates of the eSVS Mesh Saphenous Vein Graph (SVG) and control SVG at six and twenty-four months via coronary angiography and analyses of Duplex Sonography Results and coronary angiography and major cardiovascular or cerebrovascular event (MACCE)-Rate as well as analysis of preoperative great saphenous vein (GSV) duplex sonography and intra-operative GSV harvesting findings and procedure.

Detailed Description

This Study will enroll up to 100 patients total. Patients will be enrolled upon meeting certain inclusion criteria, including GSV duplex-sonography results and consent. They will be enrolled based on their clinically indicated requirement for coronary artery bypass grafting with use of their saphenous vein graft. The study will be prospective, randomized repeated measure controlled trial based on the patient's ability to receive both control and eSVS Mesh treatment. Graft patency, MACCE at 6 and 24 months after meshed and non meshed GSV graft implantation will be measured and the findings and qualification of GSV in preoperative duplex sonography will be compared with intraoperative findings while GSV harvesting in order to evaluate the safety of the eSVS mesh and the role of preoperative GSV duplex sonography.

Study Timeline

• Study Start: 2012-01
• Study First Submitted: 2012-01-03
• Study First Submitted QC: 2012-01-26
• Study First Posted: 2012-01-27
• Primary Completion: 2015-09
• Study Completion: 2015-09
• Status Verified: 2016-06
• Last Update Submitted: 2016-06-28
• Last Update Posted: 2016-06-29

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

• Patients requiring SVG CABG of the Right Coronary Artery (RCA) AND the Circumflex Artery (Cx) Systems due to atherosclerotic coronary artery disease in both of the two vessels with equal to or greater than 75% stenosis at a single site or multiple stenosis of less than 75%
• Patient with approximately sized and accessible target coronary arteries, with a minimal diameter of 1.5mm and a lack of severe calcification at the anastomotic site
• On-pump, off-pump and beating heart (beating heart with cardiopulmonary bypass) CABG.
• SVG's (eSVS Mesh treated AND non-meshed control vein graft) complying with the size requirements as outlined in the eSVS Mesh "Instructions for Use"
• CABG operational procedure must allow an eSVS Mesh implant procedure as to the eSVS Mesh Instructions for Use
• Patients equal to or greater than 21 years of age
• German language (mother tongue or fully comprehensive patients)
• Any other language with appropriate translation (fully comprehensive patients)
• The patient's accordance to CABG confirmed by a signed standardized internal informed consent for CABG
• Patient able to give their informed written consent

Exclusion Criteria

• Patients not able to give their informed written consent
• No appropriate target coronary vessel (impaired accessibility, less than 1.5mm diameter, severe calcification)
• SVG's (eSVS Mesh treated AND non-meshed control venous graft) NOT complying with the size requirements as outlined in the eSVS Mesh Instructions for Use
• CABG operational procedure, that DO NOT ALLOW an eSVS Mesh implant procedure as to the eSVS Mesh Instructions for Use
• Concomitant non-CABG cardiac procedure(s)
• Prior cardiac surgery
• Concomitant disease likely to limit life expectancy to less than 2 years
• inability to tolerate or comply with normal post-surgical drug regimen (antiplatelet plus statin)
• Inability to comply with required follow-ups, including angiography imaging methods (allergy to contrast medium, renal insufficiency with creatnine level greater than 150 mmol/l)
• Patients with a known or suspected infection in the field of operation
• Patient is pregnant or intends to become pregnant within 24 months
• Non-pregnant Patient of childbearing potential, who is not prepared for contraception during the study-period
• Concurrent participation in another interventional trial (excluding observational/survey studies)
• Foreign language (no entire comprehension of the patient information and informed study consent guaranteed)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
SVG + eSVS Mesh vs Control SVG	eSVS Mesh	Either the Circumflex Coronary Artery or the Right Coronary Artery will receive the mesh supported vein graft and the native saphenous vein as second and control graft.

Primary Outcome Measures

Name	Time	Method
Patency and number of stenosis and their degree in eSVS Mesh SVG versus Control SVG	24 Months	Severest degree of graft stenosis (in %; range 0-100) of eSVS Mesh Treated and Non-Meshed control saphenous vein grafts (SVG) assessed by angiography 24 months following CABG.

Secondary Outcome Measures

Name	Time	Method
Incidence of MACCE	30 Days, 6, 12, and 24 Months	Incidence of postoperative major adverse cardiac or cerebral events (MACCE): postoperative cerebral stroke, myocardial infarction, (Q wave and non-Q wave), post-implant coronary revascularization (Re-CABG or percutaneous coronary intervention (PCI)) and overall mortality after CABG.
Evaluation and comparison of vein characteristics of SVGs pre-operatively using duplex-sonography versus intraoperatively by standard vein harvest	Baseline	Pre-operative duplex-sonographic evaluation of the in situ saphenous vein graft charicteristics compared to intra-operative venous harvesting records.

Trial Locations

Locations (1)

University Hospital; 🇨🇭 Basel, Switzerland